MedTrace Logo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

NCT02445911 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2019-11-26

Study results available
· View outcomes & findings →

Summary

This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

KQ-791

Capsules administered orally

DRUG

Placebo

Capsules administered orally

Sponsors & Collaborators

  • Kaneq Bioscience Limited

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02445911 on ClinicalTrials.gov